Chengda Biotech announced that the company plans to make structural adjustments to 17 sub-projects under the “Human Vaccine Research and Development Project”, including 4 completed projects, 3 terminated, 1 phased suspension, 1 change in implementation method, 1 merger promotion, and 7 continued progress. The total amount of capital raised for the project remained unchanged. At the same time, it is planned to terminate the capital investment raised by the “Biotechnology Product R&D and Production Base Project”. The remaining special account for the project is 138 million yuan, and the savings raised will continue to be stored and managed by the special account. This adjustment still needs to be reviewed and approved by the company's shareholders' meeting.

Chengda Biotech announced that the company plans to make structural adjustments to 17 sub-projects under the “Human Vaccine Research and Development Project”, including 4 completed projects, 3 terminated, 1 phased suspension, 1 change in implementation method, 1 merger promotion, and 7 continued progress. The total amount of capital raised for the project remained unchanged. At the same time, it is planned to terminate the capital investment raised by the “Biotechnology Product R&D and Production Base Project”. The remaining special account for the project is 138 million yuan, and the savings raised will continue to be stored and managed by the special account. This adjustment still needs to be reviewed and approved by the company's shareholders' meeting.